Start-Up Previews (7/06)
A preview of the emerging health care companies profiled in the current, all profiles issue of Start-Up. This month's profile groups: Post-Macugen, Still In-Licensing to Uncover Value in Ophthalmology, Neurostimulation's Billion Dollar Markets, and Antibacterial Drug Development. Plus these Start-Up Across Health Care: Ascenta Therapeutics, CircuLite, CoroNovative and Endovalve.
You may also be interested in...
According to Medtech Insight’s recently published report, US Markets for Neurostimulation Products, the frontier for neural stimulation is expanding rapidly, representing a $628 million market in 2006 that is forecast to grow by over 20% each year to produce sales approaching $2 billion in 2012. Topics discussed include implantable pulse generators, device reimbursement, and current and emerging applications for neurostimulation.
High-profile experts including Anthony Fauci and Adrian Hill share views at the ICMR symposium on progressing safe COVID-19 vaccines backed by ethical trials executed with appropriate scientific rigor. Human challenge studies, "vaccine nationalism" and equitable access were among the key issues deliberated, while India committed to making its coronavirus vaccines and related capabilities available to the world.
The company has executed $400m worth of deals with smaller governments reflecting a $32-$37 price per dose for the two-shot mRNA-1273 vaccine, but said larger deals will be done at lower prices.